Cocaine-Related Disorders Clinical Trial
— CORVIOfficial title:
Benefits of Therapy With Virtual Reality Exposure in the Treatment of Cocaine Use Disorders
Cocaine addiction is a multifactorial disease with important consequences: somatic, psychiatric... The number of applications for treatment for cocaine addiction is gradually increasing from year to year but no conventional treatment is available. New tools such as virtual reality could be used in this treatment. We propose to create a virtual reality program based on the analysis of high-risk relapse situations described by patients. We will then assess the effect of this cybertherapy on patients' relapse time and their desire to use cocaine
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | December 31, 2021 |
Est. primary completion date | September 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - suffering from a cocaine use disorder with craving criteria present according to the criteria of DSM 5 - wanting to stop cocaine use - able to give informed consent to participate in research - Covered by a Social Security plan. Exclusion Criteria: Patient with: - psychiatric comorbidities (DSM 5) unstabilized - dipsomaniac alcoholism - an anteriority of one or more hypomanic or manic episodes - unstabilized psychosis - an unstabilized depression - a severe suicidal risk - a syndrome of dependence on products other than cocaine or tobacco - unstabilized anxiety - problems that hinder participation in 3D exposure, as a tendency to dissociation; phobias of the type of information (panic attacks and hypochondria...) severe dizziness... - cognitive problems limiting or preventing the possibility of implementing coping or managing emotions or stimuli and disabilities to complete questionnaires - a language barrier - a serious intercurrent pathology - the need for weekly individual follow-up Patient in a protected population such as pregnant women, lactating women, patients under guardianship, guardianship, deprived of freedoms, or in safeguarding justice |
Country | Name | City | State |
---|---|---|---|
France | CHU Clermont Ferrand | Clermont-Ferrand | Auvergne |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand | Fondation de l'Avenir, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of relapser patients at 3 months post-intervention | recovery in consumption of cocaine at M3 after intervention | day 90 after intervention | |
Secondary | Craving score | evaluation of craving score (/10) compared to inclusion score | day 30 after intervention | |
Secondary | Craving score | evaluation of craving score (/10) compared to inclusion score | day 90 after intervention | |
Secondary | Score on the personal efficiency sentiment scale | Evaluation of the score on the personal efficiency sentiment scale | day 30 after intervention | |
Secondary | Score on the personal efficiency sentiment scale | Evaluation of the score on the personal efficiency sentiment scale | day 90 after intervention | |
Secondary | Consumption of quantity of cocaine | Evaluation of quantity of cocaine consumed | day 30 after intervention | |
Secondary | Consumption of quantity of cocaine | Evaluation of quantity of cocaine consumed | day 60 after intervention | |
Secondary | Consumption of quantity of cocaine | Evaluation of quantity of cocaine consumed | day 90 after intervention | |
Secondary | Frequency of consumption of cocaine | Evaluation of the frequency of cocaine consumption | day 30 after intervention | |
Secondary | Frequency of consumption of cocaine | Evaluation of the frequency of cocaine consumption | day 60 after intervention | |
Secondary | Frequency of consumption of cocaine | Evaluation of the frequency of cocaine consumption | day 90 after intervention | |
Secondary | Way of consumption of cocaine | Evaluation of the way of cocaine consumption | day 30 after intervention | |
Secondary | Way of consumption of cocaine | Evaluation of the way of cocaine consumption | day 60 after intervention | |
Secondary | Way of consumption of cocaine | Evaluation of the way of cocaine consumption | day 90 after intervention | |
Secondary | amount of cocaine consumed during relapse | Evaluation of cocaine amount consumed during relapse | day 30 after intervention | |
Secondary | amount of cocaine consumed during relapse | Evaluation of cocaine amount consumed during relapse | day 90 after intervention | |
Secondary | Frequence of cocaine consumed during relapse | Evaluation of cocaine frequence consumption during relapse | day 30 after intervention | |
Secondary | Frequence of cocaine consumed during relapse | Evaluation of cocaine frequence consumption during relapse | day 90 after intervention | |
Secondary | Percentage of relapser patients | recovery in relapser patients at M1 after intervention | day 30 after intervention | |
Secondary | Duration of abstinence | recovery of abstinence duration | day 30 after intervention | |
Secondary | Duration of abstinence | recovery of abstinence duration | day 60 after intervention | |
Secondary | Duration of abstinence | recovery of abstinence duration | day 90 after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01526538 -
Improving Learning-based Treatment of Cocaine Dependence With Medication
|
Phase 2 | |
Completed |
NCT00877435 -
Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial
|
N/A | |
Completed |
NCT00430690 -
Acoustic Startle Reduction In Cocaine Dependence
|
||
Completed |
NCT00217997 -
Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals
|
N/A | |
Active, not recruiting |
NCT00094315 -
Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1
|
Phase 1 | |
Terminated |
NCT00142883 -
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
|
N/A | |
Completed |
NCT00218348 -
Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo
|
Phase 2 | |
Completed |
NCT00142844 -
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
|
Phase 2 | |
Completed |
NCT00158132 -
Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2
|
Phase 2 | |
Completed |
NCT00000294 -
Effects of Carvedilol on Cocaine Use in Humans - 11
|
Phase 2 | |
Completed |
NCT00015054 -
Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3
|
Phase 2 | |
Completed |
NCT00000308 -
Dextroamphetamine-Cocaine Behavioral Intervention - 5
|
Phase 2 | |
Completed |
NCT00000280 -
Glutaminergic Agents for Cocaine Abuse - 5
|
Phase 1 | |
Completed |
NCT00000278 -
Disulfiram for Cocaine-Alcohol Abuse - 3
|
Phase 2 | |
Completed |
NCT00000282 -
Pemoline for Cocaine Abuse - 7
|
Phase 2 | |
Completed |
NCT00000188 -
Selegiline in Treatment of Cocaine Dependence - 2
|
Phase 2 | |
Completed |
NCT00000277 -
Mazindol for Cocaine Abuse - 2
|
Phase 2 | |
Terminated |
NCT00000276 -
Dopamine Reuptake Inhibitors of Cocaine Abuse - 1
|
Phase 1 | |
Completed |
NCT00000314 -
M-CPP and Fenfluramine in Cocaine Addicts - 3
|
Phase 2 | |
Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 |